The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Companies   »  Icosavax Inc. (ICVX) Stock: Understanding the Vola...

Icosavax Inc. (ICVX) Stock: Understanding the Volatility

The stock of Icosavax Inc. (ICVX) has gone up by 9.31% for the week, with a 13.22% rise in the past month and a -14.73% drop in the past quarter. The volatility ratio for the week is 8.12%, and the volatility levels for the past 30 days are 6.20% for ICVX. The simple moving average for the past 20 days is 7.47% for ICVX’s stock, with a 1.36% simple moving average for the past 200 days.

Is It Worth Investing in Icosavax Inc. (NASDAQ: ICVX) Right Now?

and a 36-month beta value of 0.39. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free

The average price predicted for Icosavax Inc. (ICVX) by analysts is $23.33, which is $15.11 above the current market price. The public float for ICVX is 46.06M, and at present, short sellers hold a 2.34% of that float. On September 19, 2023, the average trading volume of ICVX was 229.94K shares.

ICVX) stock’s latest price update

Icosavax Inc. (NASDAQ: ICVX) has experienced a rise in its stock price by 10.34 compared to its previous closing price of 7.45. However, the company has seen a gain of 9.31% in its stock price over the last five trading days. Zacks Investment Research reported 2023-05-24 that Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

Analysts’ Opinion of ICVX

Many brokerage firms have already submitted their reports for ICVX stocks, with Oppenheimer repeating the rating for ICVX by listing it as a “Outperform.” The predicted price for ICVX in the upcoming period, according to Oppenheimer is $27 based on the research report published on January 04, 2023 of the current year 2023.

ICVX Trading at -0.85% from the 50-Day Moving Average

After a stumble in the market that brought ICVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.03% of loss for the given period.

Volatility was left at 6.20%, however, over the last 30 days, the volatility rate increased by 8.12%, as shares surge +11.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.23% lower at present.

During the last 5 trading sessions, ICVX rose by +9.31%, which changed the moving average for the period of 200-days by +149.85% in comparison to the 20-day moving average, which settled at $7.69. In addition, Icosavax Inc. saw 3.53% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ICVX starting from Simpson Adam K., who sale 11,788 shares at the price of $8.86 back on Jul 31. After this action, Simpson Adam K. now owns 243,930 shares of Icosavax Inc., valued at $104,459 using the latest closing price.

Kanesa-thasan Niranjan, the Chief Medical Officer of Icosavax Inc., sale 3,323 shares at $8.86 during a trade that took place back on Jul 31, which means that Kanesa-thasan Niranjan is holding 235,864 shares at $29,447 based on the most recent closing price.

Stock Fundamentals for ICVX

The total capital return value is set at -37.86, while invested capital returns managed to touch -36.48. Equity return is now at value -43.40, with -39.80 for asset returns.

Based on Icosavax Inc. (ICVX), the company’s capital structure generated 4.03 points at debt to equity in total, while total debt to capital is 3.88. Total debt to assets is 3.68, with long-term debt to equity ratio resting at 3.05. Finally, the long-term debt to capital ratio is 2.93.

The liquidity ratio also appears to be rather interesting for investors as it stands at 16.24.


To sum up, Icosavax Inc. (ICVX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.